13F filer · CIK 1652044 ↗

Alphabet Inc.

You are looking at Q4 2020. See the latest, Q2 2026 →

Reported value

$2.08B

−2.1% on the quarter before

Positions

9 new · 2 sold out

Top 10

85.9%

of the value

Est. gain

+$394.2M

on stocks held all quarter

Est. return

+38.1%

on those stocks since Q3 2020

Filed

Nov 15, 2022

On SEC EDGAR ↗

Positions as of Dec 31, 2020, from Alphabet Inc.'s 13F filing with the SEC. A 13F lists a manager's US-listed stocks and options at a quarter end and is filed up to 45 days later, so the fund may hold something else today. It leaves out short positions, cash and holdings outside the US.

Portfolio at a glance

New
Added
Cut
Same
Options

Each tile is a position, sized by its share, colored by what the fund did with it since Q3 2020. Striped tiles are options.

Lyft Inc27%

Dexcom Inc14%

Desktop Metal Inc.12%

Twilio7.7%

Arcus Biosciences Inc6.3%

Airbnb4.9%Lemonade4.8%

Relay Therapeutics Inc3.6%

Slack Technologies Inc.2.6%

Beam Therapeutics Inc2.6%

Kronos Bio Inc2.1%

Upstart1.6%

7 others1.4%

Opendoor Technologies Inc1.4%

Magenta Therapeutics Inc1.3%

Sqz Biotechnologies Co1.2%

0.8%

0.6%

0.5%

Lyft Inc27%

Dexcom Inc14%

Desktop Metal Inc.12%

Twilio7.7%

Arcus Biosciences Inc6.3%

Airbnb4.9%Lemonade4.8%

Relay Therapeutics Inc3.6%

Slack Technologies Inc.2.6%

Beam Therapeutics Inc2.6%

Kronos Bio Inc2.1%

Upstart1.6%

7 others1.4%

Opendoor Technologies Inc1.4%

Magenta Therapeutics Inc1.3%

Sqz Biotechnologies Co1.2%

0.8%

0.6%

0.5%

Largest buys

Since Q3 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Desktop Metal Inc.~$246.0MNew · 0.0% → 11.8%+14,302,438 shares
Twilio~$161.1MNew · 0.0% → 7.7%+475,859 shares
Airbnb~$101.5MNew · 0.0% → 4.9%+691,612 shares
Kronos Bio Inc~$43.0MNew · 0.0% → 2.1%+1,438,232 shares
Upstart~$33.9MNew · 0.0% → 1.6%+832,423 shares
Opendoor Technologies Inc~$28.4MNew · 0.0% → 1.4%+1,250,997 shares
Sqz Biotechnologies Co~$24.1MNew · 0.0% → 1.2%+831,389 shares
Foghorn Therapeutics Inc~$10.2MNew · 0.0% → 0.5%+500,901 shares
New Relic Inc~$6.0MNew · 0.0% → 0.3%+91,132 shares
Uber~$401,968Added · 0.1% → 0.1%+7,881 shares

Largest sells

Since Q3 2020, by estimated size: the change in shares at the quarter-end price, since a 13F gives no trade prices. Percentages are the position's share of the portfolio, before and after.

Jd Com Inc~$1.05BSold out · 49.4% → 0.0%−13,553,474 shares
Lyft Inc~$61.8MCut · 16.6% → 27.3%−1,257,985 shares
Mohawk Group Hldgs Inc~$5.4MCut · 0.3% → 0.5%−314,391 shares
Spero Therapeutics Inc~$4.3MCut · 0.6% → 0.8%−222,494 shares
Gritstone Oncology Inc~$1.5MSold out · 0.1% → 0.0%−547,488 shares
Rapt Therapeutics Inc~$94,897Cut · 1.3% → 0.8%−4,805 shares

Holdings

As of Dec 31, 2020. Changes are in shares against Sep 30, 2020, so a price move alone never reads as a buy or a sale.

Positions, sorted by share of the portfolio
#	Holding		% prev	Value	Shares		Price	Prev price
1	Lyft IncCL A COM · shares −9.8% · price +78.3%	27.3%	16.6%	$568.5M	11.6M	−9.8%	$49.13	$27.55	+78.3%	+$249.7M
2	Dexcom IncCOM · shares 0% · price −10.3%	14.3%	15.6%	$297.9M	805,681	0%	$369.72	$412.23	−10.3%	−$34.3M
3	Desktop Metal Inc.COM CL A · shares New	11.8%	—	$246.0M	14.3M	New	$17.20	—	—	—
4	TwilioCL A · shares New	7.7%	—	$161.1M	475,859	New	$338.50	—	—	—
5	Arcus Biosciences IncCOM · shares 0% · price +51.5%	6.3%	4.1%	$131.1M	5.0M	0%	$25.96	$17.14	+51.5%	+$44.5M
6	AirbnbCOM CL A · shares New	4.9%	—	$101.5M	691,612	New	$146.80	—	—	—
7	LemonadeCOM · shares 0% · price +146.4%	4.8%	1.9%	$101.0M	824,743	0%	$122.50	$49.72	+146.4%	+$60.0M
8	Relay Therapeutics IncCOM · shares 0% · price −2.4%	3.6%	3.6%	$74.9M	1.8M	0%	$41.56	$42.59	−2.4%	−$1.9M
9	Slack Technologies Inc.COM CL A · shares 0% · price +57.3%	2.6%	1.6%	$54.9M	1.3M	0%	$42.24	$26.86	+57.3%	+$20.0M
10	Beam Therapeutics IncCOM · shares 0% · price +231.6%	2.6%	0.77%	$54.2M	663,691	0%	$81.64	$24.62	+231.6%	+$37.8M
11	Kronos Bio IncCOM · shares New	2.1%	—	$43.0M	1.4M	New	$29.87	—	—	—
12	UpstartCOM · shares New	1.6%	—	$33.9M	832,423	New	$40.75	—	—	—
13	Opendoor Technologies IncCOM · shares New	1.4%	—	$28.4M	1.3M	New	$22.73	—	—	—
14	Magenta Therapeutics IncCOM · shares 0% · price +15.3%	1.3%	1.1%	$26.2M	3.3M	0%	$7.84	$6.80	+15.3%	+$3.5M
15	Sqz Biotechnologies CoCOM · shares New	1.2%	—	$24.1M	831,389	New	$28.98	—	—	—
16	Spero Therapeutics IncCOM · shares −20% · price +73.8%	0.83%	0.58%	$17.3M	889,979	−20%	$19.39	$11.16	+73.8%	+$7.3M
17	Taysha Gene Therapies IncCOM SHS · shares 0% · price +18.5%	0.82%	0.67%	$17.0M	640,882	0%	$26.54	$22.40	+18.5%	+$2.7M
18	Rapt Therapeutics IncCOM · shares −0.6% · price −38.7%	0.79%	1.3%	$16.4M	831,254	−0.6%	$19.75	$32.20	−38.7%	−$10.3M
19	Evelo Biosciences IncCOM · shares 0% · price +129.4%	0.62%	0.26%	$12.8M	1.1M	0%	$12.09	$5.27	+129.4%	+$7.2M
20	Ideaya Biosciences IncCOM · shares 0% · price +11.5%	0.51%	0.44%	$10.5M	753,187	0%	$14.00	$12.56	+11.5%	+$1.1M
21	Foghorn Therapeutics IncCOM · shares New	0.49%	—	$10.2M	500,901	New	$20.27	—	—	—
22	Mohawk Group Hldgs IncCOM · shares −35% · price +108.6%	0.48%	0.35%	$10.1M	586,327	−35%	$17.21	$8.25	+108.6%	+$5.3M
23	Fulcrum Therapeutics IncCOM · shares 0% · price +47.7%	0.38%	0.25%	$7.9M	678,141	0%	$11.71	$7.93	+47.7%	+$2.6M
24	CrowdStrikeCL A · shares 0% · price +54.2%	0.32%	0.20%	$6.6M	31,020	0%	$211.83	$137.33	+54.2%	+$2.3M
25	Autolus Therapeutics PlcSPON ADS · shares 0% · price −23.2%	0.30%	0.38%	$6.2M	698,262	0%	$8.94	$11.64	−23.2%	−$1.9M
	Total · 31 positions	100%		$2.08B						+$394.2M

The filing on SEC EDGAR ↗

Price is a stock's reported value over its shares at the quarter end. The estimated gain is the shares held at both quarter ends times the change in that price: shares bought or sold during the quarter add nothing, options are left out, and a stock split is read into the earlier share count and price.

What made money

From Q3 2020 to Q4 2020: 22 stocks held throughout, up $394.2M (+38.1%).

Lyft Inc+$249.7M+78%
Lemonade+$60.0M+146%
Arcus Biosciences Inc+$44.5M+51%
Beam Therapeutics Inc+$37.8M+232%
Slack Technologies Inc.+$20.0M+57%
Relay Therapeutics Inc−$1.9M−2%
Autolus Therapeutics Plc−$1.9M−23%
Cortexyme Inc−$4.2M−44%
Rapt Therapeutics Inc−$10.3M−39%
Dexcom Inc−$34.3M−10%

Estimated as in the holdings table: shares held at both quarter ends times the change in price; options left out.

Reported value by quarter

The total value of each quarter's 13F at that quarter end. It moves with prices as well as with buying and selling. Pick a quarter to see what the fund held then.

$110.00B$55.00B$0

Q1 201642 quartersQ2 2026

Every quarter's filing

Each quarter's 13F filing, newest first
Quarter	Filed	Reported value	Positions	Filing
Q2 2026	Aug 7, 2026	$99.08B+2,367%	28	SEC ↗
Q1 2026	May 8, 2026	$4.02B+56%	26	SEC ↗
Q4 2025	Feb 13, 2026	$2.58B+7%	29	SEC ↗
Q3 2025	Nov 7, 2025	$2.41B+13%	37	SEC ↗
Q2 2025	Aug 1, 2025	$2.14B+35%	36	SEC ↗
Q1 2025	May 2, 2025	$1.58B−8%	40	SEC ↗
Q4 2024	Feb 7, 2025	$1.72B−7%	40	SEC ↗
Q3 2024	Nov 8, 2024	$1.84B−7%	42	SEC ↗
Q2 2024	Aug 2, 2024	$1.97B−21%	42	SEC ↗
Q1 2024	May 3, 2024	$2.51B+17%	43	SEC ↗
Q4 2023	Feb 9, 2024	$2.16B+39%	44	SEC ↗
Q3 2023	Nov 13, 2023	$1.56B−16%	45	SEC ↗
Q2 2023	Aug 4, 2023	$1.86B+3%	47	SEC ↗
Q1 2023	May 11, 2023	$1.80B+5%	49	SEC ↗
Q4 2022	Feb 14, 2023	$1.72B−12%	51	SEC ↗
Q3 2022	Nov 15, 2022	$1.96B+6%	49	SEC ↗
Q2 2022	Nov 15, 2022	$1.84B−40%	55	SEC ↗
Q1 2022	Nov 15, 2022	$3.08B−26%	60	SEC ↗
Q4 2021	Nov 15, 2022	$4.14B−2%	58	SEC ↗
Q3 2021	Nov 15, 2022	$4.22B−14%	43	SEC ↗
Q2 2021	Nov 15, 2022	$4.91B+98%	36	SEC ↗
Q1 2021	Nov 15, 2022	$2.48B+19%	32	SEC ↗
Q4 2020	Nov 15, 2022	$2.08B−2%	31	SEC ↗
Q3 2020	Nov 15, 2022	$2.13B−2%	24	SEC ↗
Q2 2020	Nov 15, 2022	$2.17B+42%	24	SEC ↗
Q1 2020	Nov 15, 2022	$1.52B−8%	25	SEC ↗
Q4 2019	Nov 15, 2022	$1.65B−50%	24	SEC ↗
Q3 2019	Nov 15, 2022	$3.33B−37%	24	SEC ↗
Q2 2019	Nov 15, 2022	$5.27B+172%	22	SEC ↗
Q1 2019	Nov 15, 2022	$1.94B+129%	17	SEC ↗
Q4 2018	Nov 15, 2022	$845.8M−19%	17	SEC ↗
Q3 2018	Nov 15, 2022	$1.04B−12%	17	SEC ↗
Q2 2018	Nov 15, 2022	$1.19B+94%	17	SEC ↗
Q1 2018	Nov 15, 2022	$614.8M+67%	11	SEC ↗
Q4 2017	Nov 15, 2022	$368.6M+7%	8	SEC ↗
Q3 2017	Nov 15, 2022	$344.0M−1%	4	SEC ↗
Q2 2017	Nov 15, 2022	$347.4M+10%	4	SEC ↗
Q1 2017	Nov 15, 2022	$316.8M+8%	3	SEC ↗
Q4 2016	Nov 15, 2022	$292.8M+6%	2	SEC ↗
Q3 2016	Nov 15, 2022	$275.2M+31%	2	SEC ↗
Q2 2016	Nov 15, 2022	$209.8M−14%	3	SEC ↗
Q1 2016	Nov 15, 2022	$242.9M	5	SEC ↗